
|Videos|November 10, 2022
ENHANCE-2 Trial of Magrolimab plus Azacitidine in AML
Author(s)Hetty E. Carraway, MD, Eytan M. Stein, MD
Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































